PKAγ activators comprise a diverse array of chemical compounds that facilitate the enhancement of PKAγ's functional activity through the elevation of intracellular cyclic adenosine monophosphate (cAMP) levels or by mimicking its action. Forskolin is a potent activator that directly stimulates adenylyl cyclase, leading to an increase in cAMP, which is essential for PKAγ activation; the cAMP binds to the regulatory subunits of PKAγ, causing the release of active catalytic subunits that are then free to phosphorylate target proteins. Similarly, IBMX and Cilostamide function as non-specific and PDE3-specific inhibitors of phosphodiesterases, respectively, preventing the breakdown of cAMP, resulting in sustained activation of PKAγ. Additionally, Sp-cAMPS and 8-Br-cAMP are cAMP analogs that resist degradation and directly activate PKAγ by engaging with its regulatory subunits, while H-89, though typically a PKA inhibitor, can under certain conditions, allosterically enhance PKAγ activity.
The action of PKAγ is further potentiated by compounds like Rolipram and Dipyridamole that inhibit PDE4 and non-specific phosphodiesterases, respectively, leading to an accumulation of cAMP within the cell and consequent activation of PKAγ. Milrinone and Anagrelide, both targeting phosphodiesterase 3, increase cAMP levels, further driving the activation of PKAγ. Vinpocetine selectively inhibits phosphodiesterase 1, contributing to the rise in cAMP and subsequent PKAγ activation, while Zardaverine, also a phosphodiesterase inhibitor, enhances cAMP concentration, thereby facilitating PKAγ activation. Collectively, these activators work through interconnected pathways that converge on the elevation of cAMP or its analogs, leading to a cascade of intracellular events that activate PKAγ, which then phosphorylates various substrates to exert its physiological effects. The specificity of these chemical activators in targeting the signaling pathways that lead to PKAγ activation underscores the intricate regulatory mechanisms that modulate its activity within the cellular context.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Direct activator of adenylate cyclase, leading to increased cAMP levels, which in turn activate PKAγ by binding to the regulatory subunits causing a conformational change that releases active PKAγ catalytic subunits. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, which increases cAMP levels by preventing its degradation, thereby indirectly enhancing the activation of PKAγ through increased availability of cAMP. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Stimulates adenylate cyclase via beta-adrenergic receptors, increasing intracellular cAMP levels and consequently activating PKAγ. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
A potent and selective inhibitor of PKA, which paradoxically can upregulate PKA activity through feedback mechanisms. By inhibiting PKA, it can lead to compensatory upregulation of PKAγ levels and activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase-4 inhibitor that prevents cAMP breakdown, endorsing the accumulation of cAMP within the cell and subsequent activation of PKAγ. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Phosphodiesterase-3 inhibitor, leading to increased cAMP levels and thereby indirectly supporting the enhancement of PKAγ activity. | ||||||
Glucagon trifluoroacetic acid salt | 9007-92-5 (free base) | sc-495801 | 1 mg | $480.00 | ||
Activates adenylate cyclase in hepatocytes which elevates cAMP and activates PKAγ, influencing glucose metabolism. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Binds to its receptor and activates adenylate cyclase, increasing cAMP production and activating PKAγ. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Originally developed as a phosphodiesterase 3 inhibitor, it increases cAMP levels and activates PKAγ, studied in the research of thrombocythemia. | ||||||
NKH 477 | 138605-00-2 | sc-204130 sc-204130A | 5 mg 50 mg | $223.00 $922.00 | 1 | |
Water-soluble forskolin derivative that directly activates adenylate cyclase, thus increasing cAMP and activating PKAγ. | ||||||